Vertex Pharmaceuticals (VRTX) Cash from Operations (2009 - 2026)

Vertex Pharmaceuticals' Cash from Operations history runs 18 years deep, the most recent figure standing at 1428100000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 74.39% year-over-year to 1428100000.0 in Q1 2026; TTM through Mar 2026 was 4240600000.0, a 532.58% increase from a year earlier, with the FY2025 full-year figure at 3631400000.0, up 837.19% from the prior year.
• Cash from Operations grew to 1428100000.0 in Q1 2026 per VRTX's latest filing, from 498000000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 1428100000.0 in Q1 2026 and bottomed at 3753600000.0 in Q2 2024.
• The 5-year median for Cash from Operations is 1073100000.0 (2025), against an average of 719652941.18.
• Across the five-year window, Cash from Operations surged 670.76% in 2022 and sank 430.89% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 1078400000.0 in 2022, then plunged by 78.25% to 234600000.0 in 2023, then jumped by 149.19% to 584600000.0 in 2024, then decreased by 14.81% to 498000000.0 in 2025, then soared by 186.77% to 1428100000.0 in 2026.
• Per Business Quant, the three latest VRTX Cash from Operations figures stand at 1428100000.0 (Q1 2026), 498000000.0 (Q4 2025), and 1241400000.0 (Q3 2025).